2
Clinical Trials associated with NAI-Acne / Active, not recruitingPhase 3 Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.
/ Not yet recruitingPhase 2 Clinical efficacy and safety of NAI-Acne gel 3% applied twice-a-day to patients with facial acne vulgaris - NAI-003 3% gel efficacy pilot
100 Clinical Results associated with NAI-Acne
100 Translational Medicine associated with NAI-Acne
100 Patents (Medical) associated with NAI-Acne
100 Deals associated with NAI-Acne